The results from this study provide significant clinical evidence of the performance of Viraleze™ in humans that will support regulatory processes for the transition to the new European Medical Device Regulations (MDR), which will come into full effect in 2029. The positive data will also support ongoing marketing and commercial activities for the product.
just because something isn’t statistically significant doesn’t mean the results aren’t meaningful.
The results from this study provide significant clinical...
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.5¢ |
Change
0.005(4.55%) |
Mkt cap ! $47.38M | |||
| Open | High | Low | Value | Volume |
| 11.5¢ | 11.5¢ | 11.0¢ | $33.06K | 289.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100000 | 11.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.0¢ | 158199 | 6 |
View Market Depth
| Last trade - 15.45pm 20/05/2024 (20 minute delay) ? |
|
|||||
|
Last
11.5¢ |
Change
0.005 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 11.3¢ | 11.5¢ | 11.0¢ | 195357 | ||
| Last updated 15.47pm 20/05/2024 ? | |||||
| SPL (ASX) Chart |